disease. and there were no cases of severe illness. the immune response was wonderful. it was comparable to that seen in 16 to 25-year-olds. we know that it s safe. we know that it produces neutralizing antibodies against the virus. at one-third of the adult dose, pfizer saw no cases of myocarditis, a very rare but nown side effect, which tends to happen more often in young men a few weeks after the second dose. these several thousand pediatric-aged patients 5 through 11 have been followed for that period of time and so far have not experienced any myocarditis. reporter: any other side effects from the vaccine were mild. 9-year-old twins, marisol and alejandra gerardo, experienced a sore arm and fatigue when they got their vaccine as part of the trial back in march.
their children. erielle reshef leading us off tonight. reporter: tonight, finally a clear timeline for the 28 million young children next in line for the vaccine. if the fda authorizes the pfizer vaccine for 5 to 11-year-olds after its october 26th review, the cdc could give a final green light as early as november 3rd, less than a month from now. she s going to count for me, okay? one, two, three. reporter: 9-year-old twins marisol and alejandra gerardo got one-third of the adult dose in march as part of the trial, experiencing mild side effects like sore arm and fatigue. we felt very comfortable with the risk-based decision that we were making. now that we know, you know, hundreds of millions of people have received this vaccine, i think we feel all the more confident in the safety of the vaccine. reporter: it comes as the number of pediatric covid cases is falling, but the risk for unvaccinated children remains.
Under 12 and waiting for a COVID-19 vaccine? Here s what we know | Article cbc.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cbc.ca Daily Mail and Mail on Sunday newspapers.
Advertisement
Whenever I talk to people about vaccines, the same questions come up over and over again: have we tested them for long enough?
And how do we
really know they are going to be safe, long term?
It seems like a compelling point. The first vaccine trials started about 16 months ago. Sure, we can be confident in their short-term safety … but how do we know in a decade or two we’re not going to start turning into horrifying lizard creatures?
The answers are surprising. Vaccine trials are shorter than you might think – but time and time again, they produce safe and effective vaccines. And we probably have better data about COVID-19 vaccines at this point than almost any other vaccine we have developed.